Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety and Tolerability Study of Intralesional PV-10 Chemoablation in Subjects With Metastatic Melanoma

NCT00219843 is registered in ClinicalTrials.gov with Provectus Pharmaceuticals as lead sponsor.

NCT NCT00219843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety and Tolerability Study of Intralesional PV-10 Chemoablation in Subjects With Metastatic Melanoma
Lead sponsor
Provectus Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2005
Completion date
August 31, 2007
Enrollment
20
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma